Celldex Therapeutics Prices $300M Public Offering for Pipeline Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CLDX?
Source: seekingalpha
- Public Offering Pricing: Celldex Therapeutics has priced an underwritten public offering of approximately 10.3 million shares at $29.00 per share, expecting gross proceeds of about $300 million, which underscores the company's ability to raise capital in the market.
- Additional Share Option: The underwriters have a 30-day option to purchase up to an additional 1.55 million shares, providing the company with flexibility for further financing and potentially enhancing market confidence.
- Clear Use of Proceeds: The funds raised will support the commercial readiness and potential U.S. launch of barzolvolimab for chronic spontaneous urticaria, if approved, alongside clinical and preclinical development of product candidates, indicating the company's focus on new product initiatives.
- Stock Price Fluctuation: Following the public offering announcement, Celldex's stock price dropped about 3.5% during pre-market trading on Thursday, reflecting a cautious market reaction to the financing news, which may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLDX
Wall Street analysts forecast CLDX stock price to rise
10 Analyst Rating
9 Buy
0 Hold
1 Sell
Strong Buy
Current: 31.720
Low
24.00
Averages
55.00
High
90.00
Current: 31.720
Low
24.00
Averages
55.00
High
90.00
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celldex Therapeutics Prices $300M Public Offering for Pipeline Expansion
- Public Offering Pricing: Celldex Therapeutics has priced an underwritten public offering of approximately 10.3 million shares at $29.00 per share, expecting gross proceeds of about $300 million, which underscores the company's ability to raise capital in the market.
- Additional Share Option: The underwriters have a 30-day option to purchase up to an additional 1.55 million shares, providing the company with flexibility for further financing and potentially enhancing market confidence.
- Clear Use of Proceeds: The funds raised will support the commercial readiness and potential U.S. launch of barzolvolimab for chronic spontaneous urticaria, if approved, alongside clinical and preclinical development of product candidates, indicating the company's focus on new product initiatives.
- Stock Price Fluctuation: Following the public offering announcement, Celldex's stock price dropped about 3.5% during pre-market trading on Thursday, reflecting a cautious market reaction to the financing news, which may impact investor confidence.
See More
Celldex Therapeutics Prices Public Offering at $29 per Share
- Public Offering Pricing: Celldex Therapeutics has priced its public offering of 10.345 million shares at $29 each, expecting gross proceeds of $300 million, although the stock fell 3.45% in after-hours trading to $30.18, indicating cautious market sentiment towards the offering.
- Use of Proceeds: The net proceeds from this offering will be combined with existing cash and equivalents to fund ongoing commercial readiness and the potential launch of Barzolvolimab, if approved, while also supporting preclinical development of product candidates, demonstrating the company's commitment to drug development.
- Financial Condition Analysis: Celldex anticipates a wider net loss of $258.76 million for 2025, translating to a loss of $3.90 per share, compared to a loss of $157.86 million the previous year, reflecting high costs associated with R&D and market promotion.
- Declining Revenue Trend: The company's total revenue has decreased from $7.02 million in the prior year to $1.55 million, primarily due to reduced services under agreements with Rockefeller University, indicating challenges in revenue diversification.
See More
Celldex Announces Public Offering of Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, indicating the company's focus on reputable underwriters to ensure successful capital raising and market impact.
- Use of Proceeds: Celldex intends to utilize the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, thereby enhancing its product pipeline and competitive positioning.
- Compliance and Transparency: The offering is conducted under SEC's S-3 registration statement, ensuring compliance and transparency, which further builds investor trust in the company's governance and financial health.
See More
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at a price of $29.00 per share, expecting to raise approximately $300 million in gross proceeds, which will significantly enhance the company's financial strength to support future R&D and commercialization activities.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, reflecting strong market confidence in Celldex while providing robust capital market support for the company.
- Planned Use of Proceeds: Celldex intends to use the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, indicating the company's proactive strategy in drug development and market entry.
- Compliance and Transparency: The offering is made under a previously filed S-3 registration statement, ensuring compliance and transparency, which further enhances investor trust in Celldex and lays a solid foundation for future capital operations.
See More
Celldex Initiates Underwritten Public Offering to Support New Drug Launch
- Public Offering Launch: Celldex Therapeutics has announced the commencement of an underwritten public offering to sell shares of its common stock, with an expected 30-day option for underwriters to purchase an additional 15% of the shares to enhance financing flexibility.
- Clear Use of Proceeds: The net proceeds from this offering will be combined with existing cash and marketable securities, primarily aimed at funding the commercial readiness and launch of barzolvolimab for the treatment of chronic spontaneous urticaria, pending approval.
- Ongoing R&D Advancement: Celldex plans to utilize the offering proceeds to continue the clinical and preclinical development of its product candidates, particularly focusing on the current and future development of barzolvolimab, while also expanding its bispecific antibody platform and clinical candidates.
- Strategic Corporate Positioning: This financing not only supports new drug development but also provides funding for the development of other clinical pipeline products, demonstrating Celldex's proactive positioning for future market opportunities.
See More
Celldex's Barzolvolimab Enhances Quality of Life in Chronic Urticaria Patients
- Clinical Trial Results: Celldex presented positive data on Barzolvolimab at the 2026 American Academy of Dermatology Annual Meeting, showing that up to 51% of chronic spontaneous urticaria patients achieved complete symptom-free response at 12 weeks, increasing to 71% at 52 weeks, indicating significant efficacy in improving patient quality of life.
- Quality of Life Improvement: Among patients treated for 52 weeks, 94% had a DLQI score of 0/1 at week 52, indicating no impact of the disease on their quality of life, with 76% reporting significantly reduced impact at week 76, demonstrating the drug's long-term effectiveness.
- Broad Domain Improvement: The study revealed that Barzolvolimab significantly improved quality of life across all six DLQI domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment), indicating its potential in chronic urticaria management.
- Future Development Prospects: Celldex is conducting global Phase 3 trials, with topline data expected in Q4 2026, positioning Barzolvolimab as a potential first-line treatment for chronic urticaria and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Celldex Therapeutics Prices $300M Public Offering for Pipeline Expansion
- Public Offering Pricing: Celldex Therapeutics has priced an underwritten public offering of approximately 10.3 million shares at $29.00 per share, expecting gross proceeds of about $300 million, which underscores the company's ability to raise capital in the market.
- Additional Share Option: The underwriters have a 30-day option to purchase up to an additional 1.55 million shares, providing the company with flexibility for further financing and potentially enhancing market confidence.
- Clear Use of Proceeds: The funds raised will support the commercial readiness and potential U.S. launch of barzolvolimab for chronic spontaneous urticaria, if approved, alongside clinical and preclinical development of product candidates, indicating the company's focus on new product initiatives.
- Stock Price Fluctuation: Following the public offering announcement, Celldex's stock price dropped about 3.5% during pre-market trading on Thursday, reflecting a cautious market reaction to the financing news, which may impact investor confidence.
See More
Celldex Therapeutics Prices Public Offering at $29 per Share
- Public Offering Pricing: Celldex Therapeutics has priced its public offering of 10.345 million shares at $29 each, expecting gross proceeds of $300 million, although the stock fell 3.45% in after-hours trading to $30.18, indicating cautious market sentiment towards the offering.
- Use of Proceeds: The net proceeds from this offering will be combined with existing cash and equivalents to fund ongoing commercial readiness and the potential launch of Barzolvolimab, if approved, while also supporting preclinical development of product candidates, demonstrating the company's commitment to drug development.
- Financial Condition Analysis: Celldex anticipates a wider net loss of $258.76 million for 2025, translating to a loss of $3.90 per share, compared to a loss of $157.86 million the previous year, reflecting high costs associated with R&D and market promotion.
- Declining Revenue Trend: The company's total revenue has decreased from $7.02 million in the prior year to $1.55 million, primarily due to reduced services under agreements with Rockefeller University, indicating challenges in revenue diversification.
See More
Celldex Announces Public Offering of Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, indicating the company's focus on reputable underwriters to ensure successful capital raising and market impact.
- Use of Proceeds: Celldex intends to utilize the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, thereby enhancing its product pipeline and competitive positioning.
- Compliance and Transparency: The offering is conducted under SEC's S-3 registration statement, ensuring compliance and transparency, which further builds investor trust in the company's governance and financial health.
See More
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at a price of $29.00 per share, expecting to raise approximately $300 million in gross proceeds, which will significantly enhance the company's financial strength to support future R&D and commercialization activities.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, reflecting strong market confidence in Celldex while providing robust capital market support for the company.
- Planned Use of Proceeds: Celldex intends to use the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, indicating the company's proactive strategy in drug development and market entry.
- Compliance and Transparency: The offering is made under a previously filed S-3 registration statement, ensuring compliance and transparency, which further enhances investor trust in Celldex and lays a solid foundation for future capital operations.
See More
Celldex Initiates Underwritten Public Offering to Support New Drug Launch
- Public Offering Launch: Celldex Therapeutics has announced the commencement of an underwritten public offering to sell shares of its common stock, with an expected 30-day option for underwriters to purchase an additional 15% of the shares to enhance financing flexibility.
- Clear Use of Proceeds: The net proceeds from this offering will be combined with existing cash and marketable securities, primarily aimed at funding the commercial readiness and launch of barzolvolimab for the treatment of chronic spontaneous urticaria, pending approval.
- Ongoing R&D Advancement: Celldex plans to utilize the offering proceeds to continue the clinical and preclinical development of its product candidates, particularly focusing on the current and future development of barzolvolimab, while also expanding its bispecific antibody platform and clinical candidates.
- Strategic Corporate Positioning: This financing not only supports new drug development but also provides funding for the development of other clinical pipeline products, demonstrating Celldex's proactive positioning for future market opportunities.
See More
Celldex's Barzolvolimab Enhances Quality of Life in Chronic Urticaria Patients
- Clinical Trial Results: Celldex presented positive data on Barzolvolimab at the 2026 American Academy of Dermatology Annual Meeting, showing that up to 51% of chronic spontaneous urticaria patients achieved complete symptom-free response at 12 weeks, increasing to 71% at 52 weeks, indicating significant efficacy in improving patient quality of life.
- Quality of Life Improvement: Among patients treated for 52 weeks, 94% had a DLQI score of 0/1 at week 52, indicating no impact of the disease on their quality of life, with 76% reporting significantly reduced impact at week 76, demonstrating the drug's long-term effectiveness.
- Broad Domain Improvement: The study revealed that Barzolvolimab significantly improved quality of life across all six DLQI domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment), indicating its potential in chronic urticaria management.
- Future Development Prospects: Celldex is conducting global Phase 3 trials, with topline data expected in Q4 2026, positioning Barzolvolimab as a potential first-line treatment for chronic urticaria and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
